Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis Pharma A/S ASND announced that the European Commission has granted marketing authorization to TransCon hGH (Lonapegsomatropin Ascendis Pharma) for the treatment of growth hormone deficiency (“GHD”) in children and adolescents aged between three to 18 years. TransCon hGH is a long-acting, once-weekly prodrug of somatropin (human growth hormone or hGH) for addressing pediatric patients with GHD.
The approval in Europe was based on data from three late-stage studies — heiGHt, fliGHt and enliGHten, which evaluated TransCon hGH in more than 300 pediatric patients with GHD.
The approval in Europe was expected, as in November 2021, the European Medicine Agency’s (“EMA”) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on and recommended marketing authorization of TransCon hGH for treating pediatric GHD.
Pediatric GHD, a serious disease that affects orphans, is caused as a result of the pituitary gland’s inability to produce required amounts of growth hormone.
Shares of Ascendis have declined 24.6% in the past year compared with the industry’s decrease of 32.4%.
Image Source: Zacks Investment Research
In August 2021, the FDA approved TransCon hGH (under the trade name of Skytrofa) as a treatment for growth failure due to inadequate secretion of endogenous growth hormone in pediatric patients aged one year or above and who weigh at least 11.5 kg. The drug has the potential to replace the current standard-of-care of daily somatropin therapies, including Pfizer’s PFE Genotropin, due to its once-weekly administration.
Pfizer’s Genotropin generated $284 million in the first nine months of 2021. However, sales of the drug were down 10.1% year over year. A generic version of Pfizer’s GHD drug is also available.
Several other large as well as small pharmaceutical companies are also engaged in developing treatments for GHD, including Eli Lilly, Novo Nordisk, Pfizer, Sandoz, Merck KGaA, and Roche.
Ascendis is evaluating multiple other pipeline candidates developed using TransCon. Key among them are TransCon CNP and TransCon PTH. A phase II study is evaluating TransCon CNP for the treatment of achondroplasia, the most common form of dwarfism. TransCon PTH is being evaluated in a phase III study as a potential treatment for hypoparathyroidism in adult patients.
Zacks Rank & Other Stocks to Consider
Ascendis currently carries a Zacks Rank #2 (Buy). Top-ranked stocks in the biotech sector include Precision BioSciences, Inc. DTIL and AnaptysBio, Inc. ANAB, both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Precision BioSciences’ loss per share estimates have narrowed 6.3% for 2022, over the past 60 days.
Precision BioSciences’ earnings surpassed estimates in each of the trailing four quarters.
AnaptysBio’s loss per share estimates have narrowed 0.3% for 2022, over the past 60 days. The stock has rallied 25.4% in the past year.
AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Ascendis Pharma AS (ASND): Free Stock Analysis Report
AnaptysBio, Inc. (ANAB): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research